Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 16

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 16
---
 interested parties may write to any director or committee of our Board at c/o Secretary, Corcept Therapeutics Incorporated, 101 Redwood Shores Parkway, Redwood City, California 94065. The Secretary will refer comments or questions regarding our accounting, internal controls or auditing matters to the Audit Committee and those regarding compensation to the Compensation Committee. The Secretary will refer comments or questions regarding the nomination of directors and other corporate governance matters to the Corporate Governance and Nominating Committee.

### COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
During 2024, our Compensation Committee consisted of Messrs. Mahoney, Alton, Baker and Swisher. None of the members of our Compensation Committee is, or has been, an officer or employee of our Company. None of our named executive officers serves or in the past year has served as a member of the board of directors of any entity that has one or more named executive officers serving on our Board or Compensation Committee.

### INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The names of our executive officers, their ages as of April 17, 2025 and other information about them are set forth below:

| Name                     |     | Age |     | Position                                        |
| Joseph K. Belanoff, M.D. |     |  67 |     | Chief Executive Officer, President and Director |
| William Guyer, Pharm.D.  |     |  57 |     | Chief Development Officer                       |
| Hazel Hunt, Ph.D.        |     |  65 |     | Chief Scientific Officer                        |
| Joseph D. Lyon           |     |  47 |     | Chief Accounting and Technology Officer         |
| Sean Maduck              |     |  48 |     | President, Corcept Endocrinology                |
| Atabak Mokari            |     |  48 |     | Chief Financial Officer and Treasurer           |
| Charles Robb             |     |  62 |     | Chief Business Officer and Secretary            |

Joseph K. Belanoff, M.D. Dr. Belanoff’s biography is presented under “Nominees to Board of Directors.”

William Guyer, Pharm.D. was named our Chief Development Officer in August 2021. He brings more than 30 years of medical and clinical experience to the role, including nearly 20 years in positions of increasing seniority at Gilead Sciences. From March 2015 to August 2021, he served as Senior Vice President of